Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul 1;160(7):783-793.
doi: 10.1001/jamasurg.2025.1398.

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial

Xavier Serra-Aracil  1 , Carles Pericay  2 , Ariadna Cidoncha  1 , Jesus Badia-Closa  1   3 , Thomas Golda  4 , Esther Kreisler  4 , Pilar Hernández  5 , Eduardo Targarona  5 , Nerea Borda-Arrizabalaga  6 , Angel Reina  7 , Salvadora Delgado  8 , Eloy Espín-Bassany  9 , Aleidis Caro-Tarrago  10 , Javier Gallego-Plazas  11 , Marta Pascual  12 , Carlos Álvarez-Laso  13 , Hector Guadalajara-Labajo  14 , Ana Otero  15 , Sebastiano Biondo  4 ; TAUTEM Collaborative Group
Collaborators, Affiliations
Clinical Trial

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial

Xavier Serra-Aracil et al. JAMA Surg. .

Abstract

Importance: According to international guidelines, the standard treatment for stage T2-T3ab, N0, M0 rectal cancer is total mesorectal excision (TME), but it is associated with high morbidity and quality of life disorders.

Objective: To analyze locoregional recurrence (LR) after a follow-up of 2 years, applying a 1-sided noninferiority margin of 10%, and to assess distant recurrence (DR), overall survival (OS), and disease-free survival (DFS).

Design, setting, and participants: This was a multicenter, prospective, open-label, noninferiority, phase 3 randomized clinical trial comparing TME (TME group) with chemoradiotherapy followed by local excision with transanal endoscopic microsurgery (CRT-TEM group). This study involved 17 hospitals in Spain. Eligibility criteria included patients with rectal adenocarcinoma located lower than 10 cm from the anal verge; stage T2-T3ab N0, M0; tumor size less than or equal to 4 cm in diameter; and American Society of Anesthesiologists stage III or less with no metastasis. Sample size was calculated with a 1-sided significance level of 2.5% and a power of 80%, assuming a nonrecurrence rate of 95% in each arm and a possible loss of 15%. Randomization was performed with a 1:1 allocation ratio. Data were analyzed from July 2010 to October 2021.

Interventions: The 2 treatment groups were CRT-TEM and TME.

Main outcomes and measures: The main study outcome was LR.

Results: From July 2010 to October 2021, 173 patients (median [IQR] age, 67 [59-75] years; 116 male [67.1%]) were included (CRT-TEM, n = 86; TME, n = 87). In the 5-year modified intention-to-treat analysis, LR was 6.2% (5 of 81 patients) in the TME group and 7.4% (6 of 81 patients) in the CRT-TEM group (difference, -1.23%; 95% CI, 6.51% to -8.98%). DR was 17.3% (14 of 81 patients) in the TME group and 12.3% (10 of 81 patients) in the CRT-TEM group (difference, 4.94%; 95% CI, 15.85% to -5.98%). OS was 85.2% (69 of 81 patients) in the TME group and 82.7% (67 of 81 patients) in the CRT-TEM group (difference, 2.47%; 95% CI, 0.38%-1.78%). DFS in both groups was 88.9% (72 of 81), with a 95% CI of 9.68 to -9.68.

Conclusions and relevance: Results of this randomized clinical trial reveal that CRT-TEM achieved noninferior results compared with standard TME treatment in terms of LR and similar results in terms of DR, OS, and DFS. CRT-TEM appears to be a suitable treatment option for patients with T2-T3ab, N0, M0 rectal cancer.

Trial registration: ClinicalTrials.gov Identifier: NCT01308190.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Guadalajara reported receiving grants and personal fees from Johnson & Johnson and personal fees from Merck and Danone Nutricia outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Fodor D, Pozsgai É, Schally AV, et al. Expression levels of GHRH-Receptor, pAkt and Hsp90 predict 10-year overall survival in patients with locally advanced rectal cancer. Biomedicines. 2023;11(3):719. doi: 10.3390/biomedicines11030719 - DOI - PMC - PubMed
    1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-254. doi: 10.3322/caac.21772 - DOI - PubMed
    1. Glynne-Jones R, Wyrwicz L, Tiret E, et al. ; ESMO Guidelines Committee . Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv263. doi: 10.1093/annonc/mdy161 - DOI - PubMed
    1. National Comprehensive Cancer Network . NCCN home page. Accessed December 4, 2023. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf

Associated data